Key Points AbbVie maintains a diversified revenue base by expanding its presence in immunology, neuroscience, and oncology to offset patent cliffs. Novo Nordisk leverages its leadership in the diabetes and obesity markets to drive high net margins and steady cash flow. Which of these global drug manufacturers offers a better balance of growth and valuation for your portfolio in 2026? 10 stocks we like better than AbbVie › Choosing between AbbVie (NYSE:ABBV) and Novo Nordisk (NYSE:NVO) requires balancing a diversified income play against a focused growth leader in the massive metabolic health market during 2026. AbbVie has historically relied on blockbuster drugs while aggressively acquiring new pipelines to maintain its market share.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.